Skip to main content
Robert Avery, MD, Ophthalmology, Santa Barbara, CA

RobertLoganAveryMD

Ophthalmology Santa Barbara, CA

Retinal Disease

California Retina Consultants

Dr. Avery is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Avery's full profile

Already have an account?

  • Office

    525 E Micheltorena Street
    Ste A
    Santa Barbara, CA 93103
    Phone+1 805-963-1648

Summary

  • Robert L. Avery, MD is the founder and CEO of California Retina Consultants, Santa Barbara CA. He received his medical degree from Johns Hopkins University and took his ophthalmology training there at the Wilmer Eye Institute. He completed a vitreoretinal fellowship at Duke University under Dr. Robert Machemer, Brooks McCuen, and Gene de Juan. Dr. Avery returned to Johns Hopkins as Assistant Chief of Service and head of the trauma unit. He later went on to found California Retina Consultants, which grew into one of the largest retina practices in California and recently merged with several other national practices to form Retina Consultants of America.During the growth and expansion of CRC, Dr. Avery continued clinical and basic science research, especially in the field of angiogenesis and VEGF. He and his colleges at CRC had a role in pioneering the clinical use of anti-VEGF agents for retinal diseases. He founded the California Retina Research Foundation, which currently has over 30 active clinical research trials ongoing.
    D. Avery has received numerous honors and awards, including Senior honor awards from the American Academy of Ophthalmology and the American Society of Retina Specialists, where he also serves on the board of directors. He was the first recipient of the Ronald G. Michels Fellowship Award. He is a member of the American Academy of Ophthalmology, the Retina Society, the Macula Society, the American Society of Retinal Specialists, the Vit-Buckle Society, and the Association for Research in Vision and Ophthalmology. He is a member of the Medical Leadership Board of Retina Consultants of America.
    Dr. Avery is the co-editor of Retina Today, and he has published over 90 peer-reviewed articles on retinal diseases. His interests include the development of improved retinal drugs and their delivery, and he holds patents in retinal drug delivery. He is a partner in two ophthalmology venture capital companies, and he is on the board of several start-up

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Ophthalmology, 1988 - 1993
  • Santa Barbara Cottage Hospital
    Santa Barbara Cottage HospitalInternship, Internal Medicine, 1987 - 1988
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1987

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1993 - 2025
  • NC State Medical License
    NC State Medical License 1991 - 2003
  • MD State Medical License
    MD State Medical License 1992 - 1994
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Top Doctors:LA Area Castle Connolly, 2013
  • Top Doctors:Southern California Castle Connolly, 2012
  • Whos Who in Medicine and Healthcare Marquis Whos Who
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Market Cap of EyePoint Pharmaceuticals Inc. [EYPT] Reaches 65.23M – Now What?
    Market Cap of EyePoint Pharmaceuticals Inc. [EYPT] Reaches 65.23M – Now What?November 27th, 2020
  • EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4
    EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4November 19th, 2020
  • REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of in-Office Delivery Platform for RGX-314
    REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of in-Office Delivery Platform for RGX-314September 4th, 2019
  • Join now to see all

Professional Memberships

Other Languages

  • Spanish